Because Notch activity is elevated in HG-treated cancer cells and tissues from HER2-positive breast cancer patients with hyperglycemia, we postulated that hyperglycemia-driven NOTCH activation in breast cancer cells aggravated resistance to HER2-targeted therapy. Here, ERBB2 is linked to breast carcinoma.